Led by Koninklijke Philips’ $2.8bn acquisition of BioTelemetry, the US medical devices industry saw a rise of 5.56% in overall cross border deal activity during Q4 2020, when compared with the last four-quarter average, according to GlobalData’s deals database.
A total of 38 cross border deals worth $5.02bn were announced in Q4 2020, compared with the last four-quarter average of 36 deals.
Venture financing was the leading category in the quarter with 24 cross border deals which accounted for 63.2% of all deals.
In second place was M&A with 12 deals, followed by private equity with two transactions, respectively accounting for 31.6% and 5.3% of overall cross border deal activity in the US medical devices industry during the quarter.
In terms of value of cross border deals, M&A was the leading deal category in the US medical devices industry with total deals worth $3.44bn, while venture financing and private equity deals totalled $811.3m and $770m respectively.
US medical devices industry cross border deals in Q4 2020: Top deals
The top five medical devices industry cross border deals accounted for 82.4% of the overall value during Q4 2020.
The combined value of the top five medical devices cross border deals stood at $4.14bn, against the overall value of $5.02bn recorded for the quarter.
The top five medical devices industry cross border deals of Q4 2020 tracked by GlobalData were:
- Koninklijke Philips’ $2.8bn acquisition of BioTelemetry
- The $700m private equity deal with Verily Life Sciences by Alphabet, Ontario Teachers’ Pension Plan, Silver Lake Partners and Temasek Holdings (Private)
- AnGes’ $250m acquisition of EmendoBio
- The $200m venture financing deal with Tempus Labs by Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T Rowe Price Associates
- Weihai Weigao Shengrui Health Technology’s acquisition of Wego Healthcare Fund Holding for $188.13m.
ENDS
For more information
To gain access to our latest press releases: GlobalData Media Centre
Analysts are available for comment. Please contact the GlobalData Press Office:
EMEA & Americas: +44 207 936 6400
Asia-Pacific: +91 40 6616 6809
Email: pr@globaldata.com
For expert analysis on developments in your industry, please connect with us on:
GlobalData | LinkedIn | Twitter
Notes to Editors
This analysis considers only announced and completed deals from the GlobalData financial deals database and exclude all terminated and rumored deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
About GlobalData 4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis, and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, technology, energy, financial and professional services sectors.
